B4GALNT2

Across TCGA pan-cancer cohorts, B4GALNT2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated B4GALNT2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher B4GALNT2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated B4GALNT2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUAD, COAD, and PRAD are the cancer types where B4GALNT2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.245	0.691	<.001	36	view →
COAD	DFS	Median	All	0.407	0.788	<.001	28	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	All	0.792	0.596	.040	4	view →
BLCA	OS	Median	III,IV	0.266	0.656	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

B4GALNT2–LUAD (OS)

Open the LUAD breakdown →